Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Vehicle-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily for 6 Months in Adolescents and Adult Subjects With Stable Patchy Alopecia Areata With Optional Long-Term Open-Label Extension

Next Previous
Trial Profile

A Randomized, Double-Blind, Vehicle-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily for 6 Months in Adolescents and Adult Subjects With Stable Patchy Alopecia Areata With Optional Long-Term Open-Label Extension

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ifidancitinib (Primary)
  • Indications Alopecia areata
  • Focus Therapeutic Use
  • Sponsors Aclaris Therapeutics

Most Recent Events

  • 20 May 2020 Status changed from active, no longer recruiting to discontinued.
  • 30 Jul 2019 Planned End Date changed from 18 Jan 2020 to 13 Sep 2019.
  • 26 Jun 2019 According to an Aclaris Therapeutics media release, company will conduct a conference call at 5:00 PM today to review the results of this trial and related matters.The conference call will be webcast live over the Internet and can be accessed by logging on to the Investors page of the company website. To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 3497800 prior to the start of the call.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top